Interleukin 1 Receptor Antagonist Protein clinical trials
Also written Anakinra and Kineret.
Its developmentBy Amgen, Swedish Orphan Biovitrum and Hamad Medical, step by step14 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.How each study uses Interleukin 1 Receptor Antagonist Protein is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Interleukin 1 Receptor Antagonist Protein studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Nov 2001 · KINERET · BLA 103950 (FDA, Drugs@FDA)
- European Union
- 8 Mar 2002 · Kineret · EMEA/H/C/000363 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
164 studies that test it; most in 2020 (26); 1 more planned to start later
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 1 |
| 2008 | 5 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 11 |
| 2012 | 6 |
| 2013 | 6 |
| 2014 | 11 |
| 2015 | 4 |
| 2016 | 10 |
| 2017 | 11 |
| 2018 | 4 |
| 2019 | 11 |
| 2020 | 26 |
| 2021 | 7 |
| 2022 | 9 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 12 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 154
Virginia Commonwealth University (16) · Assistance Publique - Hôpitaux de Paris (10) · University Hospital, Basel, Switzerland (8) · Radboud University Medical Center (8) · Hellenic Institute for the Study of Sepsis (7) · Amgen (7) · Swedish Orphan Biovitrum (6) · University of California, San Diego (4)
Often tested with
Tested in the same studies.
Tocilizumab (12) · Baricitinib (4) · Empagliflozin (3) · Dexamethasone (3) · Hydroxychloroquine (3) · Adalimumab (2) · Ustekinumab (2) · Secukinumab (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 9, 3 in phase 3
Studies that test Interleukin 1 Receptor Antagonist Protein, phase 3 first.
- Dec 2026Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily TherapyPhase 3 · Assistance Publique - Hôpitaux de Paris
- Mar 2027A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG TreatmentPhase 3 · Assistance Publique - Hôpitaux de Paris
- Oct 2027Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in ChildrenPhase 3 · Istituto Giannina Gaslini
- Jan 2027Biologic Therapy to Prevent Osteoarthritis After ACL InjuryEarly Phase 1 · University of California, Los Angeles
- Feb 2027Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart FailurePhase 2 · Virginia Commonwealth University
- Jun 2027Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)Phase 2 · Baylor Research Institute
- Aug 2027BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema ReductionEarly Phase 1 · Northwestern University
- Oct 2027A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell TherapyPhase 2 · Memorial Sloan Kettering Cancer Center
- Nov 2027Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCTPhase 1/2 · Ruijin Hospital
Studies
Open first, then newest update. How each study uses Interleukin 1 Receptor Antagonist Protein is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 168
- Interleukin-1 Inhibition to Improve the Response of Myeloproliferative Neoplasms Resistant to Cytoreductive TreatmentNot yet recruitingPhase 2University Hospital, BrestNCT07946289Written as Anakinra
- Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in ChildrenRecruitingPhase 3Istituto Giannina GasliniNCT05805930Written as Anakinra
- Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear DiseaseRecruitingPhase 2Andrea VambutasNCT03587701Written as Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingPhase 3UMC UtrechtNCT02735707Written as Anakinra
- Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCTNot yet recruitingPhase 1/2Ruijin HospitalNCT07888348Written as Anakinra
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialRecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT06381661Written as Anakinra
- Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic StrokeRecruitingPhase 2Beijing Tiantan HospitalNCT07423975Written as High-dose Anakinra
- Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)RecruitingPhase 2Baylor Research InstituteNCT04926467Written as Anakinra
- "IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ"RecruitingPhase 1/2Nantes University HospitalNCT07503834Written as Anakinra 100Mg/0.67Ml Inj Syringe
- Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or OlderNot yet recruitingPhase 1University of Southern CaliforniaNCT07838974Written as Anakinra
- BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema ReductionNot yet recruitingEarly Phase 1Northwestern UniversityNCT07410312Written as Anakinra
- Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)Not yet recruitingPhase 1University of North Carolina, Chapel HillNCT07600190Written as Anakinra 100 Mg/0.67 Ml Inj Syringe
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Anakinra
- Anakinra for the Treatment of Postprandial Hypoglycemia in a Patient With Total Gastrectomy and End-Stage Renal DiseaseNot yet recruitingPhase 2Marc DonathNCT07580079Written as Anakinra (interleukin-1 receptor antagonist)
- Randomised Evaluation of COVID-19 TherapyRecruitingPhase 3University of OxfordNCT04381936Written as Anakinra
- Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODSRecruitingPhase 2/3Nationwide Children's HospitalNCT05267821Written as Anakinra
- ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITISNot yet recruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT07371689Written as Anakinra, KINERET®
- Biologic Therapy to Prevent Osteoarthritis After ACL InjuryRecruitingEarly Phase 1University of California, Los AngelesNCT03968913Written as Anakinra injection
- Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid SyndromeRecruitingPhase 2/3Hellenic Institute for the Study of SepsisNCT05926505Written as Anakinra 149 MG/ML Prefilled Syringe [Kineret]
- Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm InfantsRecruitingPhase 2Monash Medical CentreNCT07254000Written as Anakinra (Kineret®)
See all 168 studies that test Interleukin 1 Receptor Antagonist Protein →
Given beside what is tested · 6 — Interleukin 1 Receptor Antagonist Protein is usual care or a partner of the new treatment
- Dupilumab_Metastatic NSCLCActive, not recruitingPhase 1/2Thomas MarronNCT05013450Written as Anakinra
- Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer PatientsCompletedPhase 1Goethe UniversityNCT04942626Written as Kineret 100 MG in 0.67 ML Prefilled Syringe
- Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITISCompletedPhase 2/3Institut National de la Santé Et de la Recherche Médicale, FranceNCT00339157Written as Anakinra
- Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)CompletedPhase 1/2University of AlbertaNCT03182426Written as Anakinra
- Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple MyelomaCompletedPhase 1/2Juno Therapeutics, a Subsidiary of CelgeneNCT03430011Written as JCARH125 + anakinra
- A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate CancerTerminatedPhase 1Tceleron Therapeutics, Inc.NCT04227275Written as Anakinra
As the comparator · 4 — what is tested is compared with Interleukin 1 Receptor Antagonist Protein
- COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"Not yet recruitingPhase 3Yale UniversityNCT07281027Written as Anakinra
- A Study of JNJ-77474462 in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04544813Written as Anakinra
- A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation StudyCompletedPhase 1Handok Inc.NCT02175056Written as Kineret(Anakinra)
- The SPECTRA StudyTerminatedPhase 2AmgenNCT00537667Written as anakinra
What changed recently
From the registry's own updates since Oct 19, 2026.
Started recruiting1
- Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in ChildrenNov 18, 2026NCT05805930
Stopped1
- Non Inferiority KawasakI Trial With AnakinraWithdrawnOct 26, 2026NCT06697431
Newly registered2
- Interleukin-1 Inhibition to Improve the Response of Myeloproliferative Neoplasms Resistant to Cytoreductive TreatmentNov 18, 2026NCT07946289
- Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCTOct 22, 2026NCT07888348
Codes
What other systems call Interleukin 1 Receptor Antagonist Protein · ClinicalTrials.gg INT008888
- MeSH (NLM) D053590Interleukin 1 Receptor Antagonist ProteinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 9013DUQ28KANAKINRAConfirmed FDA, NLM
- RxNorm 72435One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D053590 | Interleukin 1 Receptor Antagonist Protein | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 9013DUQ28K | ANAKINRA | Confirmed FDA, NLM |
| RxNorm | 72435 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.